Characteristic chromatogram detection method and quality detection method of Danqi medicinal preparation

Detection of the characteristic map of Dan Qi tablets through high-performance liquid chromatography has solved the problem of incomplete quality control of Dan Qi tablets in the existing technology, and achieved simultaneous measurement and quality control of multiple components to ensure the safety of Dan Qi tablets. and effectiveness.

CN118961944AInactive Publication Date: 2024-11-15TONG REN TANG TECH CO LTD
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
CN202411242606.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-05
Publication Date
2024-11-15
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

The existing Dan Qipian detection method cannot detect and comprehensively control its quality from a whole, resulting in insufficient information and incomplete component detection.

Method used

The detection method was adopted by high-performance liquid chromatography, using octadecylsilane bonded silica gel as the filler, and acetonitrile and phosphoric acid aqueous solution were mobile phases. The detection wavelength was 200nm and the column temperature was 35℃. This way, we can obtain the characteristic map of Dan Qipian and perform quality control.

Benefits of technology

It has achieved reliable and stable quality control of Danqi tablets, and can measure a variety of ingredients at the same time, including sodium danshenin, protocatechaldehyde, rosemary acid, cyperoxalic acid, panaxanthin saponin R1, danshenic acid B, ginseng saponin The content of Rg1, ginseng saponin Re, danphenol acid E, ginseng saponin Rb1, and ginseng saponin Rd ensures the safety and effectiveness of Danqi Tablets.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118961944A_ABST
    Figure CN118961944A_ABST
Patent Text Reader

Abstract

The invention relates to the technical field of traditional Chinese medicine detection, and provides a detection method and a quality detection method of a characteristic chromatogram of a Danqi medicinal preparation, the detection method adopts high performance liquid chromatography for detection, and chromatographic conditions are as follows: octadecylsilane chemically bonded silica is used as a filler; the method comprises the following steps of: performing gradient elution by using acetonitrile as a mobile phase A and a 0.05-0.2% (v / v) phosphoric acid aqueous solution as a mobile phase B, and performing characteristic chromatogram collection, similarity evaluation and characteristic peak identification on a prepared sample to be detected under the chromatographic conditions to complete quality control of the Danqi tablets. The method has the advantages of being simple, convenient, good in stability and repeatability, high in precision and the like, the quality control method of the compound preparation Danqi tablets containing the radix salviae miltiorrhizae and the radix notoginseng in the prescription can be perfected, it is guaranteed that the quality of the Danqi tablets is reliable and stable, and the quality of the Danqi tablets can be comprehensively and effectively controlled on the whole; therefore, the safety, effectiveness and controllable quality of the Danqi tablets are ensured.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of traditional Chinese medicine detection, and in particular to a method for detecting a characteristic spectrum of a Radix Angelicae Pubescentis drug preparation and a method for detecting the quality of the drug. Background Art

[0002] Danshen is the dried root and rhizome of Salvia miltiorrhiza Bge., a plant of the Labiatae family. It was first recorded in the Shennong's Herbal Classic and was listed as a top grade. Danshen has the effects of promoting blood circulation and removing blood stasis, relieving pain by menstruation, clearing the heart and removing vexation, cooling blood and eliminating carbuncle. Danshen has long been known as "one Danshen powder, the same effect as Siwu Decoction", which fully illustrates the role of Danshen in promoting blood circulation and removing blood stasis, relieving pain by menstruation. Panax notoginseng is the dried root and rhizome of Panax notoginseng (Burk.) FHChen, a plant of the Araliaceae family. It was first recorded in the Compendium of Materia Medica. It has the effects of dispersing blood stasis and stopping bleeding, reducing swelling and relieving pain. As an "important medicine for traumatology", Panax notoginseng can be used for bleeding diseases such as hemoptysis, hematemesis, epistaxis, traumatic bleeding, and chest and abdominal pain, swelling and pain from falls, etc.

[0003] Modern chemical research shows that Danshen mainly contains fat-soluble diterpenoid quinone components (such as tanshinone, cryptotanshinone, etc.) and water-soluble phenolic acid components (salvianolic acid, protocatechuic aldehyde, sodium danshensu, etc.), which have multiple pharmacological effects such as anti-inflammatory, antioxidant, and anti-tumor. Panax notoginseng from the Araliaceae family mainly contains rich saponin components (notoginseng saponin R1, ginsenoside Rg1, ginsenoside Rb1, ginsenoside Rd, etc.), and modern pharmacological research shows that Panax notoginseng has pharmacological effects such as anti-thrombotic, anti-inflammatory, antioxidant, and cardiovascular protection.

[0004] The quality of traditional Chinese medicine directly affects the efficacy of the product, and the quality control link of traditional Chinese medicine is the last checkpoint to ensure the safety and effectiveness of the medicine. In the 2020 edition of the Chinese Pharmacopoeia, the identification item of Danqi Tablets tested the index components of Panax notoginseng, including ginsenoside Rg1, ginsenoside Rb1, notoginsenoside R1, and the index component salvianolic acid B in Salvia miltiorrhiza. The content of ginsenoside Rg1, ginsenoside Rb1 and notoginsenoside R1 was determined under the content determination item, but the content of the main components in Salvia miltiorrhiza was not determined.

[0005] The emergence of Chinese medicine fingerprints provides a multi-level, all-round quality assurance for the designation of Chinese medicine quality standards, which is in line with the idea of ​​TCM's "holistic concept" to study Chinese medicine quality evaluation. As an important means of Chinese medicine quality evaluation, Chinese medicine fingerprints can provide all-round chemical (biological) information of Chinese medicine, and can evaluate the quality of Chinese medicine from an overall level, making up for the current limitation of only using one or several components as indicators for Chinese medicine identification and content determination.

[0006] Danqi Tablets are made by crushing Panax notoginseng into fine powder, boiling, filtering, concentrating, adding Panax notoginseng fine powder, starch and dextrin, pressing and coating to obtain Chinese medicine tablets. It has the effects of promoting blood circulation, removing blood stasis, unblocking meridians and relieving pain. It is used for chest pain, dizziness and headache, and abdominal pain during menstruation caused by blood stasis. In the prescription, Salvia miltiorrhiza is slightly cold and has the effects of promoting blood circulation, nourishing blood, removing blood stasis and unblocking meridians; Panax notoginseng is warm in nature and has the effects of promoting blood circulation, stopping bleeding, removing blood stasis and relieving pain. The two medicines are used together to promote blood circulation, remove blood stasis, nourish blood and generate new blood. It can promote blood circulation, dilate coronary arteries, regulate blood pressure, and is a good medicine for treating heart stasis and chest pain. It can also be used for headache, dizziness and abdominal pain during menstruation in women. The existing quality control method of Danqi Tablets is to identify the characteristics of Panax notoginseng in the prescription by microscopy, and to identify the characteristic component of Danshen, salvianolic acid B, and the representative components of Panax notoginseng, ginsenoside Rg1, ginsenoside Rb1 and notoginsenoside R1 by thin layer chromatography, and the content determination only detects ginsenoside Rg1, ginsenoside Rb1 and notoginsenoside R1. Therefore, the current information obtained from the detection or identification of Danqi Tablets is small, and the components identified are small, so it is impossible to detect and control its quality as a whole. Summary of the invention

[0007] Therefore, the technical problem to be solved by the present invention is to overcome the defect that the detection or identification of Danqi tablets in the prior art cannot detect and comprehensively control its quality as a whole, thereby providing a detection method and a quality detection method for the characteristic spectrum of Danqi pharmaceutical preparations, which can ensure that the quality of Danqi tablets is reliable and stable, and can effectively control the quality of Danqi tablets as a whole, comprehensively and effectively.

[0008] To this end, the present invention provides the following technical solutions:

[0009] A method for detecting a characteristic spectrum of a Danqi drug preparation comprises detecting it by high performance liquid chromatography, wherein the chromatographic conditions are:

[0010] Octadecylsilane bonded silica gel was used as filler; acetonitrile was used as mobile phase A, 0.05-0.2% (v / v) phosphoric acid aqueous solution was used as mobile phase B, and the gradient elution procedure was as follows:

[0011] 0-10 min, the volume ratio of mobile phase A to mobile phase B is 7%:93% → 18%:82%;

[0012] 10-50 min, the volume ratio of mobile phase A to mobile phase B is 18%:82% → 22%:78%;

[0013] 50-60 min, the volume ratio of mobile phase A to mobile phase B is 22%:78% → 30%:70%;

[0014] 60-75 min, the volume ratio of mobile phase A to mobile phase B is 30%:70% → 45%:55%;

[0015] 75-80 min, the volume ratio of mobile phase A to mobile phase B is 45%:55% → 70%:30%;

[0016] 80-85 min, the volume ratio of mobile phase A to mobile phase B is 70%:30%→7%:93%.

[0017] Optionally, the chromatographic conditions include at least one of the following conditions:

[0018] (1) The phosphoric acid concentration in mobile phase B is 0.1%;

[0019] (2) The mobile phase flow rate is 0.8-1.2 ml / min, preferably, the mobile phase flow rate is 1 ml / min;

[0020] (3) The column oven temperature is 30-40°C, preferably, the column oven temperature is 35°C;

[0021] (4) The injection volume is 5-20 μL, preferably, the injection volume is 10 μL;

[0022] (5) The detection wavelength is 190-220 nm, preferably, the detection wavelength is 200 nm;

[0023] (6) The column length of the chromatographic column is 100-300 mm, the inner diameter is 2.1-5.0 mm, and the particle size is 1.8-10 μm. Preferably, the column length of the chromatographic column is 250 mm, the inner diameter is 4.6 mm, and the particle size is 5 μm.

[0024] Optionally, a method for preparing a test solution is also included, comprising:

[0025] Add extraction solvent to the test sample for extraction, filter, and take the filtrate to obtain the test sample solution.

[0026] Optionally, the extraction solvent is at least one of water, methanol and ethanol;

[0027] Preferably, the extraction solvent is 30-70% (v / v) methanol aqueous solution and / or 30-70% (v / v) ethanol aqueous solution;

[0028] Preferably, the solid-liquid ratio of the mass of the test sample to the volume of the extraction solvent used is (1-4): (25-100), and the unit of the solid-liquid ratio is g / ml;

[0029] Preferably, the extraction step adopts ultrasonic extraction, the ultrasonic power is 300-600W, the frequency is 20-60kHz, and the extraction time is 10-60min.

[0030] Optionally, it further comprises a reference solution, wherein the reference solution comprises a reference substance solution and a reference medicinal material solution;

[0031] Preferably, the method for preparing a reference solution, wherein the reference comprises at least one of notoginsenoside R1, ginsenoside Rg1, ginsenoside Rb1, ginsenoside Rd, ginsenoside Re, rosmarinic acid, lithospermic acid, sodium danshensu, salvianolic acid E, salvianolic acid B, and protocatechuic aldehyde;

[0032] Preferably, each 1 ml of the reference solution contains 150-250 μg of notoginsenoside R1; and / or,

[0033] Each 1 ml of the reference solution contains 100-200 μg of ginsenoside Rg1; and / or,

[0034] Each 1 ml of the reference solution contains ginsenoside Rb 500-1500 μg; and / or,

[0035] Each 1 ml of the reference solution contains ginsenoside Rd 50-150 μg; and / or,

[0036] Each 1 ml of the reference solution contains ginsenoside Re 50-150 μg; and / or,

[0037] Each 1 ml of the reference solution contains 2-20 μg of rosmarinic acid; and / or,

[0038] Each 1 ml of the reference solution contains 2-20 μg of lithospermic acid; and / or,

[0039] Each 1 ml of the reference solution contains 10-50 μg of sodium danshensu; and / or,

[0040] Each 1 ml of the reference solution contains 10-50 μg of salvianolic acid E; and / or,

[0041] Each 1 ml of the reference solution contains 50-200 μg of salvianolic acid B; and / or,

[0042] Each 1 ml of the reference solution contains 2 to 20 μg of protocatechuic aldehyde;

[0043] Preferably, the method further comprises a preparation method of a control medicinal material solution, wherein an extraction solvent is added to the control medicinal material for extraction, filtering, and taking a filtrate to obtain a test solution;

[0044] Preferably, in the method for preparing the control medicinal material solution, the extraction solvent is at least one of water, methanol and ethanol;

[0045] Preferably, in the method for preparing the control medicinal material solution, the solid-liquid ratio of the mass of the test sample to the volume of the extraction solvent used is (1-4): (25-100), and the unit of the solid-liquid ratio is g / ml;

[0046] Preferably, in the preparation method of the control medicinal material solution, the extraction step adopts ultrasonic extraction, the ultrasonic power is 300-600W, the frequency is 20-60kHz, and the extraction time is 10-60min.

[0047] Preferably, the control medicinal materials are Danshen decoction pieces and / or Panax notoginseng powder.

[0048] A method for determining the content of Danqi pharmaceutical preparation, comprising:

[0049] Take the test solution and the reference solution, and respectively detect them by the high performance liquid chromatography method in the characteristic spectrum detection method of Danqi pharmaceutical preparation described in any one of claims 1-5.

[0050] A quality testing method for Danqi pharmaceutical preparations, comprising:

[0051] The step of obtaining a characteristic spectrum of the test sample according to the characteristic spectrum detection method of Danqi pharmaceutical preparation, and comparing the characteristic spectrum with the reference fingerprint spectrum;

[0052] The control fingerprint spectrum is obtained by fitting the characteristic spectrum obtained by using at least one batch of Danqi pharmaceutical preparations according to the detection method of the characteristic spectrum of Danqi pharmaceutical preparations.

[0053] Optionally, the control fingerprint includes 19 characteristic peaks: peak 1, peak 2, peak 3, peak 4, peak 5, peak 6, peak 7, peak 8, peak 9, peak 10, peak 11, peak 12, peak 13, peak 14, peak 15, peak 16, peak 17, peak 18 and peak 19;

[0054] Taking peak 12 as the reference peak (S), the specified values ​​of the relative retention times of peaks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 13, 14, 15, 16, 17, 18 and 19 are 0.155, 0.170, 0.225, 0.254, 0.345, 0.557, 0.571, 0.692, 0.735, 0.804, 0.906, 1.039, 1.088, 1.114, 1.233, 1.640, 1.741 and 1.779, respectively;

[0055] The relative retention times of peaks 1 to 11, peaks 13 to 19 and peak S are within the range of ±10% of the specified value.

[0056] Optionally, peak No. 1 is sodium danshensu, peak No. 4 is protocatechuic aldehyde, peak No. 9 is rosmarinic acid, peak No. 10 is lithospermic acid, peak No. 11 is notoginseng saponin R1, peak No. 12 is salvianolic acid B, peak No. 14 is ginsenoside Rg1, peak No. 15 is ginsenoside Re, peak No. 16 is salvianolic acid E, peak No. 17 is ginsenoside Rb1, and peak No. 18 is ginsenoside Rd.

[0057] The method for detecting the characteristic spectrum of the Danqi pharmaceutical preparation, the method for determining the content of the Danqi pharmaceutical preparation, and the method for detecting the quality of the Danqi pharmaceutical preparation are characterized in that the Danqi pharmaceutical preparation includes Danqi tablets, Danqi capsules or Danqi soft capsules.

[0058] The technical solution of the present invention has the following advantages:

[0059] 1. A method for detecting a characteristic spectrum of a Danqi pharmaceutical preparation provided by the present invention comprises detecting by high performance liquid chromatography, wherein the chromatographic conditions are: using octadecylsilane bonded silica gel as a filler; using acetonitrile as a mobile phase A, using a 0.05-0.2% (v / v) phosphoric acid aqueous solution as a mobile phase B, and following the following gradient elution procedure: 0 to 10 min, the volume ratio of mobile phase A to mobile phase B is 7%:93%→18%:82%; 10 to 50 min, the volume ratio of mobile phase A to mobile phase B is 18%:82%→22%:78%; 50 to 60 min, The volume ratio of mobile phase A to mobile phase B is 22%:78%→30%:70%; from 60 to 75 minutes, the volume ratio of mobile phase A to mobile phase B is 30%:70%→45%:55%; from 75 to 80 minutes, the volume ratio of mobile phase A to mobile phase B is 45%:55%→70%:30%; from 80 to 85 minutes, the volume ratio of mobile phase A to mobile phase B is 70%:30%→7%:93%; the above chromatographic conditions are used to collect characteristic spectra, evaluate similarity and identify characteristic peaks of the prepared samples to complete the quality control of Danqi tablets. This method has the advantages of simplicity, good stability and repeatability, high precision, etc. It can improve the quality control method of Danqi tablets, a compound preparation containing salvia miltiorrhiza and Panax notoginseng in the prescription, and can simultaneously determine the contents of danshensu sodium, protocatechuic aldehyde, rosmarinic acid, lithospermic acid, notoginseng saponin R1, salvianolic acid B, ginsenoside Rg1, ginsenoside Re, salvianolic acid E, ginsenoside Rb1, and ginsenoside Rd, thereby ensuring the reliable and stable quality of Danqi tablets and being able to carry out overall, comprehensive and effective quality control of Danqi tablets, thereby ensuring the safety, effectiveness and quality control of Danqi tablets.

[0060] Furthermore, the characteristic spectrum of Danqi tablets was detected by the above method, and the chromatographic conditions were stable, the chromatogram baseline was stable, the common chromatographic peaks were evenly distributed, the peak shape was good, and the peak separation was excellent. BRIEF DESCRIPTION OF THE DRAWINGS

[0061] In order to more clearly illustrate the specific implementation methods of the present invention or the technical solutions in the prior art, the drawings required for use in the specific implementation methods or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are some implementation methods of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.

[0062] Figure 1 It is the characteristic spectrum of 15 batches of Danqi tablets in Example 1 of the present invention;

[0063] Figure 2 is the reference fingerprint in Example 1 of the present invention;

[0064] Figure 3 It is a comparison diagram of the characteristic spectrum of the reference solution in Example 1 of the present invention and the reference fingerprint spectrum of Danqi tablets;

[0065] Figure 4 is the spectrum (190-400nm) of each reference substance in Example 1 of the present invention;

[0066] Figure 5 This is a comparison of the characteristic spectrum of Danshen reference medicinal material in Example 1 of the present invention and the fingerprint spectrum of Danqi tablets reference

[0067] Figure 6 It is a comparison diagram of the characteristic spectrum of the reference medicinal material of Panax notoginseng and the reference fingerprint diagram of Danqi tablets in Example 1 of the present invention;

[0068] Figure 7 It is the characteristic spectrum of Danqi tablets at different wavelengths in Example 2 of the present invention;

[0069] Figure 8 is a characteristic spectrum of different elution gradients of Danqi tablets in Example 3 of the present invention;

[0070] Fig. 9 is the characteristic spectrum of Danqi tablets at different flow rates in Example 4 of the present invention;

[0071] Fig.10 It is the characteristic spectrum of Danqi tablets at different column temperatures in Example 5 of the present invention. DETAILED DESCRIPTION

[0072] The following examples are provided for a better understanding of the present invention, but are not intended to limit the best mode of implementation, nor to limit the content and protection scope of the present invention. Any product identical or similar to the present invention obtained by anyone under the inspiration of the present invention or by combining the features of the present invention with other prior arts shall fall within the protection scope of the present invention.

[0073] If no specific experimental steps or conditions are specified in the examples, the conventional experimental steps or conditions described in the literature in the field can be used. If no manufacturer is specified for the reagents or instruments used, they are all conventional reagent products that can be obtained commercially.

[0074] The instruments and reagents used in the following examples are:

[0075] instrument:

[0076] Waters E2695 high performance liquid chromatograph (Waters, USA); Mettler Toledo XP205 electronic balance (Mettler Toledo, Switzerland); Mettler Toledo ML204 electronic balance (Mettler Toledo, Switzerland); KQ-500DE CNC ultrasonic cleaner (Kunshan Ultrasonic Instrument Co., Ltd.); high-speed universal pulverizer (Tianjin Test Instrument Co., Ltd.)

[0077] Chromatographic columns: KR100-5-C18 (4.6×250 mm, 5 μm) (Kromasil Ltd., Sweden), Agilent Zorbax SB-C18 (4.6 mm×250 mm, 5 μm) (Agilent Ltd., USA).

[0078] Reagents: Acetonitrile and phosphoric acid were of chromatographic grade, water was ultrapure water, and methanol was of analytical grade.

[0079] Trial drug: Danqi tablets (provided by Beijing Tong Ren Tang Technology Development Co., Ltd. Pharmaceutical Factory with batch numbers: 21120205, 21122518, 21122519, 21122522, 21122525, 21122526, 21122527, 22120206, 22120207, 22120208, 23120210, 23120211, 23120213, 23125680; provided by Fuzhou Minhai Pharmaceutical Co., Ltd., batch number: 23100131).

[0080] Reference substances: notoginsenoside R1 (batch number: 110745-201921), ginsenoside Rg1 (batch number: 110703-202034), ginsenoside Rb1 (batch number: 110704-202129), ginsenoside Rd (batch number: 111818-201603), ginsenoside Re (batch number: 110754-202028), danshensu sodium (batch number: 110855-201915), danshenol Acid B (batch number: 111562-201111), protocatechuic aldehyde (batch number: 110810-202210), and rosmarinic acid (batch number: 111871-202408) were provided by the China Food and Drug Inspection Institute; salvianolic acid E (batch number: WP24012307, content: 98.03%) and lithospermic acid (batch number: WP23060109, content: 99.31%) were provided by Sichuan Weikeqi Biotechnology Co., Ltd.

[0081] Example 1

[0082] This embodiment provides a method for establishing a characteristic spectrum of Danqi tablets, comprising the following steps: using high performance liquid chromatography for detection, the chromatographic conditions are: the chromatographic column is KR100-5-C18 (4.6×250mm, 5μm); the mobile phase flow rate is 1.0ml / min; the column oven temperature is 35°C; the injection volume is 10μL, and the detection wavelength is 200nm. Acetonitrile is used as mobile phase A, 0.1% (v / v) phosphoric acid aqueous solution is used as mobile phase B, and the following gradient elution program is followed: 0-10min, the volume ratio of mobile phase A and mobile phase B is 7%:93%→18%:82%;

[0083] 10-50 min, the volume ratio of mobile phase A to mobile phase B is 18%:82% → 22%:78%;

[0084] 50-60 min, the volume ratio of mobile phase A to mobile phase B is 22%:78% → 30%:70%;

[0085] 60-75 min, the volume ratio of mobile phase A to mobile phase B is 30%:70% → 45%:55%;

[0086] 75-80 min, the volume ratio of mobile phase A to mobile phase B is 45%:55% → 70%:30%;

[0087] 80-85 min, the volume ratio of mobile phase A to mobile phase B is 70%:30%→7%:93%. The theoretical plate number is not less than 3000 calculated based on the notoginsenoside R1 peak.

[0088] Preparation of test solution: Take an appropriate amount of Danqi tablets, crush them, take about 1g, accurately weigh, put it in a stoppered conical flask, accurately add 25ml of 50% (v / v) methanol, stopper it, weigh it, extract it with ultrasound (power 500W, frequency 40kHz) for 30min, cool it, weigh it again, make up the lost weight with 50% methanol, shake it well, filter it, take the filtrate, and pass it through a 0.45μm microporous filter membrane to obtain the solution.

[0089] Preparation of control medicinal material solution: Take Danshen decoction pieces, crush them, take about 3g, accurately weigh, put them in a stoppered conical bottle, accurately add 25ml of methanol, seal them, weigh them, treat them with ultrasound (power 500W, frequency 40kHz) for 30min, let them cool, weigh them again, make up the lost weight with methanol, shake them well, filter them, take the filtrate, pass it through a 0.45μm microporous filter membrane, and get it. Take Panax notoginseng powder, about 3g, accurately weigh, put them in a stoppered conical bottle, accurately add 25ml of methanol, seal them, weigh them, treat them with ultrasound (power 500W, frequency 40kHz) for 30min, let them cool, weigh them again, make up the lost weight with methanol, shake them well, filter them, take the filtrate, pass it through a 0.45μm microporous filter membrane, and get it.

[0090] Preparation of reference solution: Notoginsenoside R1, ginsenoside Rg1, ginsenoside Rb1, ginsenoside Rd, ginsenoside Re, danshensu sodium, salvianolic acid B, protocatechuic aldehyde, rosmarinic acid, salvianolic acid E, lithospermic acid, accurately weighed, added with 70% (v / v) methanol to make a solution containing notoginsenoside R1 193.46 μg, ginsenoside Rg1 158.48 μg, ginsenoside Rb1 117.26 μg, ginsenoside Rd 96.71 μg, ginsenoside Re 73.71 μg, danshensu sodium 33.92 μg, salvianolic acid B 91.42 μg, protocatechuic aldehyde 7.81 μg, rosmarinic acid 10.02 μg, salvianolic acid E per 1 ml. The mixed solution of 26.17μg of sodium pyruvate and 9.50μg of lithospermic acid was shaken well and filtered through a 0.45μm microporous filter to obtain the reference solution.

[0091] Determination method: Accurately pipette 10 μL of test solution, reference solution and reference medicinal material solution respectively and inject into liquid chromatograph for determination.

[0092] Take 15 batches of Danqi tablets, prepare the test solution according to the above method, and measure it to obtain the characteristic spectrum of each batch of Danqi tablets. The results are shown in Figure 1In the figure, S1-S15 correspond to 21120205, 21122518, 21122519, 21122522, 21122525, 21122526, 21122527, 22120206, 22120207, 22120208, 23120210, 23120211, 23120213, 23125680, 23100131, and R represents the reference fingerprint of Danqi tablets. The collected liquid phase data of 15 batches of Danqi tablets were imported into the "Chinese Medicine Chromatographic Fingerprint Similarity Evaluation System" (Version 2.0), and 19 chromatographic peaks contained in the 15 batches of samples were selected as common peaks to generate the reference fingerprint of Danqi tablets (R), and the relative retention time and relative peak area of ​​each common peak were calculated. The results are shown in Tables 1 and 2, and the reference fingerprint is shown in Figure 2 .

[0093] The “Chinese Medicine Chromatographic Fingerprint Similarity Evaluation System” (Version 2.0) compiled by the Pharmacopoeia Committee was used to evaluate the similarity of the characteristic spectrum data of 15 batches of Danqi tablets. The similarities were all greater than 0.9. The results are shown in Table 3.

[0094] Table 1 Retention time and relative retention time of common peaks in fingerprints of 15 batches of Danqi tablets

[0095]

[0096] Table 1 Retention time and relative retention time of common peaks in fingerprints of 15 batches of Danqi tablets

[0097]

[0098]

[0099] Table 2 Peak areas and relative peak areas of common peaks in fingerprints of 15 batches of Danqi tablets

[0100]

[0101]

[0102]

[0103] Table 2: Peak areas and relative peak areas of common peaks in fingerprints of 15 batches of Danqi tablets

[0104]

[0105]

[0106] Table 3 Similarity calculation results of fingerprint spectra of 15 batches of Danqi tablets

[0107]

[0108] Table 3 Similarity calculation results of fingerprints of 15 batches of Danqi tablets

[0109]

[0110]

[0111] Characteristic peak identification

[0112] The reference solution was tested according to the above-mentioned HPLC method and compared with the reference fingerprint of Danqi Tablets. Figure 3 and Figure 4 ,

[0113] The control medicinal material solution was tested according to the above-mentioned HPLC method, and the results are shown in Figure 5 (Comparison of fingerprints of Danshen reference medicinal material and Danqi tablets reference medicinal material) and Figure 6 (Comparison of fingerprints of Panax notoginseng reference drug and Danqi tablets reference drug).

[0114] It was finally confirmed that the control fingerprint of Danqi tablets included 19 characteristic peaks, including peak 1, peak 2, peak 3, peak 4, peak 5, peak 6, peak 7, peak 8, peak 9, peak 10, peak 11, peak 12, peak 13, peak 14, peak 15, peak 16, peak 17, peak 18 and peak 19; peak 1 is sodium danshensu, peak 4 is protocatechuic aldehyde, peak 9 is rosmarinic acid, peak 10 is lithospermic acid, peak 11 is notoginseng saponin R1, peak 12 is salvianolic acid B, peak 14 is ginsenoside Rg1, peak 15 is ginsenoside Re, peak 16 is salvianolic acid E, peak 17 is ginsenoside Rb1, and peak 18 is ginsenoside Rd.

[0115] The rule of relative retention time of each characteristic peak is as follows: taking peak 12 (salvianolic acid B) as the reference peak (S), the specified values ​​of relative retention time of peak 1, peak 2, peak 3, peak 4, peak 5, peak 6, peak 7, peak 8, peak 9, peak 10, peak 11, peak 13, peak 14, peak 15, peak 16, peak 17, peak 18 and peak 19 are 0.155, 0.170, 0.225, 0.254, 0.345, 0.557, 0.571, 0.692, 0.735, 0.804, 0.906, 1.039, 1.088, 1.114, 1.233, 1.640, 1.741 and 1.779 respectively;

[0116] Among them, the relative retention times of peaks 1 to 11, peaks 13 to 19 and peak S are within the range of ±10% of the specified value.

[0117] When the characteristic spectrum detection method of Danqi tablets of this embodiment is used to control the quality of Danqi tablets, the test sample of Danqi tablets is detected according to the characteristic spectrum detection method of Danqi tablets, and the characteristic spectrum of the test sample is compared with the control fingerprint spectrum of Danqi tablets. If at least 19 characteristic peaks identical to those in the control fingerprint spectrum appear in the characteristic spectrum of the test sample, peak No. 12 (salvianolic acid B) is used as the reference peak (S), and peaks 1 to 11, peaks 13 to 19 and peak S are calculated, and their relative retention times are within the range of ±10% of the specified value, then the quality of the test sample of Danqi tablets is qualified, otherwise it is unqualified. The above-mentioned quality control method is more specific and comprehensive for the quality control of Danqi tablets, and can standardize, normalize and objectively evaluate the quality of Danqi tablets.

[0118] Example 2 Investigation of detection wavelength

[0119] Taking the detection wavelength as a variable, Danqi tablets (batch number 22120207) were taken to prepare a test solution according to Example 1, and the characteristic spectra at different wavelengths were obtained; wherein the detection wavelengths were 200nm, 240nm, 280nm, and 330nm, respectively. The results are shown in Figure 7 . Figure 7 The corresponding wavelengths from bottom to top are 200nm, 240nm, 280nm, and 330nm.

[0120] By comparing the experimental results, it can be seen that when the detection wavelength is 200nm, the chromatographic peak data of the characteristic spectrum obtained is the largest, the response value is the best, and the separation between the peaks is better. Therefore, 200nm is preferably used as the detection wavelength.

[0121] Example 3 Investigation of the gradient elution procedure

[0122] Taking the gradient elution program as a variable, the test was performed according to the gradient elution program in the table below. Danqi tablets (batch number 22120207) were taken to prepare the test solution according to Example 1, and the fingerprints of different gradient elution programs were obtained. The results are shown in Figure 8 , Figure 8 From bottom to top, they correspond to gradient elution gradients 1-4.

[0123] Table 4 Elution gradient 1

[0124] Time (min) Mobile phase A% (v / v) Mobile phase B% (v / v) 0~10 12→18 88→82 10~50 18→22 82→78 50~60 22→30 78→70 60~75 30→45 70→55 75~80 45→70 55→30 80~85 70→12 30→88

[0125] Table 5 Elution gradient 2

[0126]

[0127]

[0128] Table 6 Elution gradient 3

[0129] Time (min) Mobile phase A% (v / v) Mobile phase B% (v / v) 0~10 10→18 90→82 10~50 18→22 82→78 50~60 22→32 78→68 60~70 32→45 68→55 70~75 45→10 55→90

[0130] Table 7 Elution gradient 4

[0131] Time (min) Mobile phase A% (v / v) Mobile phase B% (v / v) 0~10 7→18 93→82 10~50 18→22 82→78 50~60 22→30 78→70 60~75 30→45 70→55 75~80 45→70 55→30 80~85 70→7 30→93

[0132] It can be seen from the results that under the condition of elution gradient 4, the separation degree of each chromatographic peak is high and the peak shape is good. Therefore, elution gradient 4 is selected as the elution gradient for the characteristic spectrum detection of Danqi tablets.

[0133] Example 4 Investigation of flow rate

[0134] Taking flow rate as a variable, Danqi tablets (batch number 22120207) were taken to prepare a test solution according to Example 1, and the solution was measured to obtain characteristic spectra at different flow rates; wherein, flow rate 1: 0.8 ml / min; flow rate 2: 1 ml / min.

[0135] Results Fig. 9 The results showed that the chromatographic peak separation under the two flow rate conditions was not much different, but the chromatographic peak separation at flow rate 1 was poor, so flow rate 2 was selected as the flow rate for the characteristic spectrum of Danqi tablets.

[0136] Example 5 Investigation of column temperature

[0137] Taking column temperature as a variable, Danqi tablets (batch number 22120207) were taken to prepare a test solution according to Example 1, and the solution was measured to obtain characteristic spectra at different column temperatures; wherein, column temperature 1: 35°C; column temperature 2: 40°C.

[0138] Results Fig.10 The results showed that the chromatographic peak separation and peak shape under the two column temperature conditions were not much different. After comprehensive consideration, a column temperature of 35°C was selected as the column temperature for the characteristic spectrum of Danqi tablets.

[0139] Methodological review of experimental cases

[0140] 1. Precision

[0141] A batch of Danqi tablets (batch number: 22120207) was prepared according to the preparation method of the test solution in Example 1, and the sample was injected 6 times continuously. The characteristic spectrum was detected, and the retention time and peak area calculation results were shown in Tables 8-9. The results showed that the relative retention time RSD of each chromatographic peak was less than 1% and the relative peak area met the requirements of the fingerprint spectrum in the Chinese Pharmacopoeia.

[0142] Table 8 Precision calculation results (retention time and relative retention time)

[0143]

[0144] Table 8 Precision calculation results (retention time and relative retention time)

[0145]

[0146] Table 9 Precision calculation results (peak area and relative peak area)

[0147]

[0148]

[0149] Table 9 Precision calculation results (peak area and relative peak area)

[0150]

[0151]

[0152] 2. Stability

[0153] Take a batch of Danqi tablets (batch number: 22120207), prepare according to the preparation method of the test solution in Example 1, and detect the characteristic spectrum, and inject the sample to detect the characteristic spectrum at 0, 3, 6, 9, 12, 18, and 24 hours respectively. The retention time and peak area calculation results are shown in Tables 10-11. The results show that the relative retention time and relative peak area of ​​each chromatographic peak meet the requirements of the fingerprint spectrum.

[0154] Table 10 Stability calculation results (retention time and relative retention time)

[0155]

[0156] Table 10 Continued stability calculation results (retention time and relative retention time)

[0157]

[0158]

[0159] Table 11 Stability calculation results (peak area and relative peak area)

[0160]

[0161] Table 11 Continued stability calculation results (peak area and relative peak area)

[0162]

[0163]

[0164] 3. Repeatability

[0165] Take a batch of Danqi tablets (batch number: 22120207), prepare 6 test sample solutions according to the test sample preparation method in Example 1, detect the characteristic spectrum, and the retention time and peak area calculation results are shown in Tables 12-13. The results show that the retention time of each chromatographic peak and the similarity of the chromatographic peak meet the requirements of the characteristic spectrum.

[0166] Table 12 Calculation results of repeatability experiment (retention time and relative retention time)

[0167]

[0168]

[0169] Table 12 Continuation of the calculation results of repeatability experiment (retention time and relative retention time)

[0170]

[0171] Table 13 Repeatability experimental calculation results (peak area and relative peak area)

[0172]

[0173]

[0174] Table 13 Continuation of repeatability experimental calculation results (peak area and relative peak area)

[0175]

[0176] Obviously, the above embodiments are merely examples for the purpose of clear explanation, and are not intended to limit the implementation methods. For those skilled in the art, other different forms of changes or modifications can be made based on the above description. It is not necessary and impossible to list all the implementation methods here. The obvious changes or modifications derived therefrom are still within the scope of protection of the invention.

Claims

1. A method for detecting the characteristic spectrum of a Radix Angelicae Pubescentis drug preparation, characterized in that: Including high performance liquid chromatography detection, the chromatographic conditions are: Octadecylsilane bonded silica gel was used as filler; acetonitrile was used as mobile phase A, 0.05-0.2% (v / v) phosphoric acid aqueous solution was used as mobile phase B, and the gradient elution procedure was as follows: 0-10 min, the volume ratio of mobile phase A to mobile phase B is 7%:93% → 18%:82%; 10-50 min, the volume ratio of mobile phase A to mobile phase B is 18%:82% → 22%:78%; 50-60 min, the volume ratio of mobile phase A to mobile phase B is 22%:78% → 30%:70%; 60-75 min, the volume ratio of mobile phase A to mobile phase B is 30%:70% → 45%:55%; 75-80 min, the volume ratio of mobile phase A to mobile phase B is 45%:55% → 70%:30%; 80-85 min, the volume ratio of mobile phase A to mobile phase B is 70%:30%→7%:93%.

2. The method for detecting the characteristic spectrum of the Danqi pharmaceutical preparation according to claim 1, characterized in that: The chromatographic conditions include at least one of the following conditions: (1) The phosphoric acid concentration in mobile phase B is 0.1%; (2) The mobile phase flow rate is 0.8-1.2 ml / min, preferably, the mobile phase flow rate is 1 ml / min; (3) The column oven temperature is 30-40°C, preferably, the column oven temperature is 35°C; (4) The injection volume is 5-20 μL, preferably, the injection volume is 10 μL; (5) The detection wavelength is 190-220 nm, preferably, the detection wavelength is 200 nm; (6) The column length of the chromatographic column is 100-300 mm, the inner diameter is 2.1-5.0 mm, and the particle size is 1.8-10 μm. Preferably, the column length of the chromatographic column is 250 mm, the inner diameter is 4.6 mm, and the particle size is 5 μm.

3. The method for detecting the characteristic spectrum of the Radix Angelicae Pubescentis pharmaceutical preparation according to any one of claims 1 to 2, characterized in that: Also included is a method for preparing a test solution, comprising: Add extraction solvent to the test sample for extraction, filter, and take the filtrate to obtain the test sample solution.

4. The method for detecting the characteristic spectrum of the Danqi pharmaceutical preparation according to claim 3, characterized in that: The extraction solvent is at least one of water, methanol and ethanol; Preferably, the extraction solvent is 30-70% (v / v) methanol aqueous solution and / or 30-70% (v / v) ethanol aqueous solution; Preferably, the solid-liquid ratio of the mass of the test sample to the volume of the extraction solvent used is (1-4): (25-100), and the unit of the solid-liquid ratio is g / ml; Preferably, the extraction step adopts ultrasonic extraction, the ultrasonic power is 300-600W, the frequency is 20-60kHz, and the extraction time is 10-60min.

5. The method for detecting the characteristic spectrum of the Danqi pharmaceutical preparation according to any one of claims 1 to 4, characterized in that: Also included is a reference solution, wherein the reference solution includes a reference substance solution and a reference medicinal material solution; Preferably, the method for preparing a reference solution, wherein the reference comprises at least one of notoginsenoside R1, ginsenoside Rg1, ginsenoside Rb1, ginsenoside Rd, ginsenoside Re, rosmarinic acid, lithospermic acid, sodium danshensu, salvianolic acid E, salvianolic acid B, and protocatechuic aldehyde; Preferably, each 1 ml of the reference solution contains 150-250 μg of notoginsenoside R1; and / or, Each 1 ml of the reference solution contains 100-200 μg of ginsenoside Rg1; and / or, Each 1ml of reference solution contains ginsenoside Rb 500-1500μg; and / or, Each 1ml of the reference solution contains ginsenoside Rd 50-150μg; and / or, Each 1 ml of the reference solution contains ginsenoside Re 50-150 μg; and / or, Each 1 ml of the reference solution contains 2-20 μg of rosmarinic acid; and / or, Each 1 ml of the reference solution contains 2-20 μg of lithospermic acid; and / or, Each 1 ml of the reference solution contains 10-50 μg of sodium danshensu; and / or, Each 1 ml of the reference solution contains 10-50 μg of salvianolic acid E; and / or, Each 1 ml of the reference solution contains 50-200 μg of salvianolic acid B; and / or, Each 1 ml of the reference solution contains 2 to 20 μg of protocatechuic aldehyde; Preferably, the method further comprises a preparation method of a control medicinal material solution, wherein an extraction solvent is added to the control medicinal material for extraction, filtering, and taking a filtrate to obtain a test solution; Preferably, in the method for preparing the control medicinal material solution, the extraction solvent is at least one of water, methanol and ethanol; Preferably, in the method for preparing the control medicinal material solution, the solid-liquid ratio of the mass of the test sample to the volume of the extraction solvent used is (1-4): (25-100), and the unit of the solid-liquid ratio is g / ml; Preferably, in the preparation method of the control medicinal material solution, the extraction step adopts ultrasonic extraction, the ultrasonic power is 300-600W, the frequency is 20-60kHz, and the extraction time is 10-60min. Preferably, the control medicinal materials are Danshen decoction pieces and / or Panax notoginseng powder.

6. A method for determining the content of Danqi pharmaceutical preparation, characterized in that: include: Take the test solution and the reference solution, and respectively detect them by the high performance liquid chromatography method in the characteristic spectrum detection method of Danqi pharmaceutical preparation described in any one of claims 1-5.

7. A quality detection method for Danqi pharmaceutical preparations, characterized in that: include: A step of obtaining a characteristic spectrum of the test sample according to the characteristic spectrum detection method of Danqi pharmaceutical preparation according to any one of claims 1 to 5, and comparing the characteristic spectrum with the reference fingerprint spectrum; The control fingerprint spectrum is obtained by fitting the characteristic spectrum obtained by using at least one batch of Danqi pharmaceutical preparations according to the detection method of the characteristic spectrum of Danqi pharmaceutical preparations according to any one of claims 1-5.

8. The quality detection method of Danqi pharmaceutical preparation according to claim 7 is characterized in that, The control fingerprint spectrum includes 19 characteristic peaks: peak 1, peak 2, peak 3, peak 4, peak 5, peak 6, peak 7, peak 8, peak 9, peak 10, peak 11, peak 12, peak 13, peak 14, peak 15, peak 16, peak 17, peak 18 and peak 19; Taking peak 12 as the reference peak (S), the specified values ​​of the relative retention times of peaks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 13, 14, 15, 16, 17, 18 and 19 are 0.155, 0.170, 0.225, 0.254, 0.345, 0.557, 0.571, 0.692, 0.735, 0.804, 0.906, 1.039, 1.088, 1.114, 1.233, 1.640, 1.741 and 1.779, respectively; The relative retention times of peaks 1 to 11, peaks 13 to 19 and peak S are within the range of ±10% of the specified value.

9. The quality detection method of Danqi pharmaceutical preparation according to claim 8, characterized in that: The peak No. 1 is sodium danshensu, the peak No. 4 is protocatechuic aldehyde, the peak No. 9 is rosmarinic acid, the peak No. 10 is lithospermic acid, the peak No. 11 is notoginseng saponin R1, the peak No. 12 is salvianolic acid B, the peak No. 14 is ginsenoside Rg1, the peak No. 15 is ginsenoside Re, the peak No. 16 is salvianolic acid E, the peak No. 17 is ginsenoside Rb1, and the peak No. 18 is ginsenoside Rd.

10. The method for detecting the characteristic spectrum of the Danqi pharmaceutical preparation according to any one of claims 1 to 5, the method for determining the content of the Danqi pharmaceutical preparation according to claim 6, and the method for detecting the quality of the Danqi pharmaceutical preparation according to any one of claims 7 to 9, characterized in that: The Danqi pharmaceutical preparations include Danqi tablets, Danqi capsules or Danqi soft capsules, etc.

Citation Information

Patent Citations

  • Compound salvia miltiorrhiza tablet fingerprint detection method

    CN104111292A

  • Quality control method for salvia miltiorrhiza injection

    CN104749308A

  • Preparation method and application of standard reference substance of salvia miltiorrhiza formula granules

    CN117783333A

  • Chinese medicine preparation for treating cardiovascular and cerebrovascular diseases and preparing process thereof

    CN1669573A

  • Quality detection method for compound prepn of red sage and notoginseng

    CN1772041A